- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT02611674
Methodology Study of Novel Outcome Measures to Assess Progression of ALS
23 oktober 2019 bijgewerkt door: Biogen
Methodology Study of Novel Electrophysiological, Physical, and Imaging Outcome Measures to Assess the Progression of Amyotrophic Lateral Sclerosis
The primary objectives of the study are to estimate and rank-order the longitudinal standardized mean changes over 6 months and over 12 months, for a set of outcome measures administered to participants with amyotrophic lateral sclerosis (ALS), in order to identify measures that are more sensitive to disease progression than Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R).
The secondary objectives of this study are: To evaluate the test-retest reproducibility of each outcome measure; To determine correlations between 6 and 12-month changes in all exploratory measures with 18 and 24-month changes in ALSFRS-R and survival; To assess correlations between/among the various measures; To obtain biological samples in order to identify molecular correlates to the clinical measures and to further characterize previously identified and novel molecular biomarkers of disease progression for incorporation into future clinical studies.
Studie Overzicht
Toestand
Voltooid
Conditie
Studietype
Observationeel
Inschrijving (Werkelijk)
138
Contacten en locaties
In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.
Studie Locaties
-
-
-
Leuven, België, 3000
- UZ Leuven
-
-
-
-
Ontario
-
Toronto, Ontario, Canada, M4N 3M5
- Sunnybrook Health Sciences Centre
-
-
Quebec
-
Montréal, Quebec, Canada, H3A 2B4
- Montreal Neurological Institute Clinical Research Unit
-
-
-
-
-
Berlin, Duitsland, 13125
- Charité - Campus Virchow-Klinikum
-
Hannover, Duitsland, 30625
- Medizinische Hochschule Hannover
-
Jena, Duitsland, 07743
- Universitaetsklinikum Jena
-
Ulm, Duitsland, 89081
- Universitaetsklinikum Ulm
-
-
-
-
Hérault
-
Montpellier, Hérault, Frankrijk, 34295
- Hopital Gui de Chauliac, Service de Neurologie
-
-
Paris
-
Paris cedex 13, Paris, Frankrijk, 75013
- Groupe Hospitalier Pitie-Salpetriere
-
-
-
-
-
Dublin, Ierland, Dublin 9
- Beaumont Hospital
-
-
-
-
CX
-
Utrecht, CX, Nederland, 3584
- UMC Utrecht
-
-
-
-
West Midlands
-
Sheffield, West Midlands, Verenigd Koninkrijk, S102JF
- Royal Hallamshire Hospital
-
-
-
-
California
-
San Diego, California, Verenigde Staten, 92103
- University of California San Diego Medical Center
-
San Francisco, California, Verenigde Staten, 94115
- California Pacific Medical Center
-
-
Florida
-
Tampa, Florida, Verenigde Staten, 33612
- University of South Florida
-
-
Georgia
-
Atlanta, Georgia, Verenigde Staten, 30322
- The Emory Clinic
-
-
Maryland
-
Baltimore, Maryland, Verenigde Staten, 21287
- Johns Hopkins Hospital
-
-
Massachusetts
-
Charlestown, Massachusetts, Verenigde Staten, 2129
- Massachusetts General Hospital, MA
-
-
Missouri
-
Saint Louis, Missouri, Verenigde Staten, 63110
- Washington University School of Medicine
-
-
Pennsylvania
-
Hershey, Pennsylvania, Verenigde Staten, EC037
- Penn State Milton S. Hershey Medical Center
-
-
-
-
-
St. Gallen, Zwitserland, 9007
- Kantonsspital St. Gallen
-
-
Deelname Criteria
Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
16 jaar tot 85 jaar (Kind, Volwassen, Oudere volwassene)
Accepteert gezonde vrijwilligers
Nee
Geslachten die in aanmerking komen voor studie
Allemaal
Bemonsteringsmethode
Kanssteekproef
Studie Bevolking
Participants suffering from ALS are recruited by participating physicians in a standard clinical practice setting.
Beschrijving
Key Inclusion Criteria:
- A diagnosis of sporadic or familial ALS
- ALS onset within ≤5 years
- Must be 16 to 85 years of age, inclusive, for sites in the United States and 18 to 85 years of age, inclusive, for all sites outside of the United States
Key Exclusion Criteria:
- History of or positive test result at Screening for human immunodeficiency virus (HIV)
- History of or positive test result at Screening for hepatitis C virus (HCV) antibody or hepatitis B virus (HBV)
- Possibility of neuromuscular weakness other than ALS
- Unspecified reasons that, in the opinion of the site Investigator, make the subject unsuitable for enrollment or unlikely to be able to complete, at a minimum, the Month 6 Visit
NOTE: Other protocol defined Inclusion/ Exclusion criteria may apply
Studie plan
Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.
Hoe is de studie opgezet?
Ontwerpdetails
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Longitudinal standardized mean change in electrophysiological measures as assessed by electrical impedance myography (EIM)
Tijdsspanne: Baseline to Month 6 and Baseline to Month 12
|
EIM is an electrophysiological technique in which current is applied to a muscle of interest and resultant voltage and impedance are measured.
These measured parameters reflect the conductivity of underlying tissue and presumably the pathologic state of denervated muscle in an ALS participant
|
Baseline to Month 6 and Baseline to Month 12
|
|
Longitudinal standardized mean change in electrophysiological measures as assessed by compound muscle action potential (CMAP)
Tijdsspanne: Baseline to Month 6 and Baseline to Month 12
|
CMAP is a standard electrophysiological measure generated by maximally stimulating a nerve such that all muscle fibers innervated by the respective nerve are depolarized.
Reduction of CMAP amplitude reflects loss of motor axons and, therefore, is directly relevant to ALS.
|
Baseline to Month 6 and Baseline to Month 12
|
|
Longitudinal standardized mean change in electrophysiological measures as assessed by motor unit number estimation (MUNE)
Tijdsspanne: Baseline to Month 6 and Baseline to Month 12
|
Optional, to be administered at each site's Investigator's discretion.
MUNE is used to estimate the number of functioning motor units.
|
Baseline to Month 6 and Baseline to Month 12
|
|
Longitudinal standardized mean change in electrophysiological measures as assessed by motor unit number index (MUNIX)
Tijdsspanne: Baseline to Month 6 and Baseline to Month 12
|
MUNIX estimates functioning motor units within a muscle.
CMAP and surface electromyography potentials (surface interference patterns) are obtained at various levels of voluntary effort, and MUNIX is estimated using power and area of CMAP and surface interference patterns.
|
Baseline to Month 6 and Baseline to Month 12
|
|
Longitudinal standardized mean change in muscle strength measures as assessed by hand-held dynamometry (HHD)
Tijdsspanne: Baseline to Month 6 and Baseline to Month 12
|
HHD tests isometric strength of multiple muscles using standard participant positioning.
Approximately 10 muscle groups will be examined (per each side) in both upper and lower extremities.
|
Baseline to Month 6 and Baseline to Month 12
|
|
Longitudinal standardized mean change in respiratory measures as assessed by slow vital capacity (SVC)
Tijdsspanne: Baseline to Month 6 and Baseline to Month 12
|
Vital capacity will be measured by means of an SVC test, administered in the upright position.
Upright SVC will be determined by performing 3 to 5 measures, in accordance with criteria established by the American Thoracic Society and the European Respiratory Society.
|
Baseline to Month 6 and Baseline to Month 12
|
|
Longitudinal standardized mean change in functional measures as assessed by Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R)
Tijdsspanne: Baseline to Month 6 and Baseline to Month 12
|
The ALSFRS-R has been demonstrated to predict survival.
The ALSFRS-R measures 4 functional domains, including respiratory, bulbar function, gross motor skills, and fine motor skills.
There are a total of 12 questions, each scored from 0 to 4 for a total possible score of 48 [Cedarbaum 1999], with higher scores representing better function.
|
Baseline to Month 6 and Baseline to Month 12
|
Secundaire uitkomstmaten
Uitkomstmaat |
Tijdsspanne |
|---|---|
|
Within-participant test-retest reliability between the 2 repeated measurements occurring on Day 1 and Day 7 for EIM
Tijdsspanne: Day 1 and Day 7
|
Day 1 and Day 7
|
|
Within-participant test-retest reliability between the 2 repeated measurements for CMAP
Tijdsspanne: Day 1 and Day 7
|
Day 1 and Day 7
|
|
Within-participant test-retest reliability between the 2 repeated measurements for MUNE
Tijdsspanne: Day 1 and Day 7
|
Day 1 and Day 7
|
|
Within-participant test-retest reliability between the 2 repeated measurements for MUNIX
Tijdsspanne: Day 1 and Day 7
|
Day 1 and Day 7
|
|
Within-participant test-retest reliability between the 2 repeated measurements for HHD
Tijdsspanne: Day 1 and Day 7
|
Day 1 and Day 7
|
|
Within-participant test-retest reliability between the 2 repeated measurements for SVC
Tijdsspanne: Day 1 and Day 7
|
Day 1 and Day 7
|
|
Within-participant test-retest reliability between the 2 repeated measurements for ALSFRS-R
Tijdsspanne: Day 1 and Day 7
|
Day 1 and Day 7
|
|
Comparison between 6 and 12-month changes in exploratory measures with 18 and 24-month changes in ALSFRS-R and survival
Tijdsspanne: Baseline to Month 24
|
Baseline to Month 24
|
|
Comparison between 6-month changes for muscle electrophysiological measures
Tijdsspanne: Baseline to Month 12
|
Baseline to Month 12
|
|
Comparison between 6-month changes for muscle strength measures
Tijdsspanne: Baseline to Month 12
|
Baseline to Month 12
|
|
Comparison between 6-month changes for functional measures
Tijdsspanne: Baseline to Month 12
|
Baseline to Month 12
|
|
Comparison of molecular biomarkers with disease progression
Tijdsspanne: Baseline to Month 12
|
Baseline to Month 12
|
Medewerkers en onderzoekers
Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.
Sponsor
Studie record data
Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.
Bestudeer belangrijke data
Studie start (Werkelijk)
6 januari 2016
Primaire voltooiing (Werkelijk)
27 juli 2018
Studie voltooiing (Werkelijk)
1 augustus 2019
Studieregistratiedata
Eerst ingediend
8 oktober 2015
Eerst ingediend dat voldeed aan de QC-criteria
19 november 2015
Eerst geplaatst (Schatting)
23 november 2015
Updates van studierecords
Laatste update geplaatst (Werkelijk)
24 oktober 2019
Laatste update ingediend die voldeed aan QC-criteria
23 oktober 2019
Laatst geverifieerd
1 oktober 2019
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
- Pathologische processen
- Metabole ziekten
- Ziekten van het centrale zenuwstelsel
- Ziekten van het zenuwstelsel
- Neuromusculaire aandoeningen
- Neurodegeneratieve ziekten
- Ziekten van het ruggenmerg
- TDP-43 Proteïnopathieën
- Proteostase-tekortkomingen
- Sclerose
- Motor Neuron Ziekte
- Amyotrofische laterale sclerose
Andere studie-ID-nummers
- 999AS003
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .